Placebo Response in Depression: A Perspective for Clinical Practice
By Arif Khan, Shirin Khan
Paroxetine—The Antidepressant from Hell? Probably Not, But Caution Required
By Robert M. Nevels, Samuel T. Gontkovsky, Bryman E. Williams
Paroxetine Treatment of Depression in Late Life
By Charles F. Reynolds III, MD
Optimizing Treatment Outcomes for Patients With Depression and Generalized Anxiety Disorder
By Michael E. Thase, MD, and Madhukar Trivedi, MD
New Developments in the Neurobiological Basis of Anxiety Disorders
By Jack M. Gorman, MD, Robert M. A. Hirschfeld, MD, and Philip T. Ninan, MD
New Developments in Depression and Anxiety Disorders
By Charles B. Nemeroff, MD, PhD
Management of Late-Life Depression: Focus on Comorbid Conditions
By Warren D. Taylor, MD, and K. Ranga Rama Krishnan, MB, ChB
Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder
By Richard C. Josiassen, John M. Kane, Grace S. Liang, Joshua Burke, Christopher F. O’Brien
Long-Term Antidepressant Treatment
By Katia K. Delrahim, BA, Rachel Maddux, BA, and Mark Hyman Rapaport, MD